GUSELKUMAB MAINTAINS RESOLUTION OF DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS THROUGH 2 YEARS FROM A PHASE 3 STUDY

Rahman P, Mcinnes I, Deodhar A, Schett G, Mease PJ, Shawi M, Cua D, Sherlock J, Kollmeier A, Xu XL, Jiang Y, Sheng S, Ritchlin CT, Mcgonagle D (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Publisher: BMJ PUBLISHING GROUP

City/Town: LONDON

Pages Range: 826-827

Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES

DOI: 10.1136/annrheumdis-2022-eular.1337

Authors with CRIS profile

Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

Janssen Pharmaceutica NV BE Belgium (BE) Oregon Health and Science University (OSHU) US United States (USA) (US) Janssen Global Services, LLC US United States (USA) (US) University of Leeds GB United Kingdom (GB) University of Rochester (UR) US United States (USA) (US) University of Glasgow GB United Kingdom (GB) Memorial University of Newfoundland (MUN) CA Canada (CA) Swedish Medical Center US United States (USA) (US)

How to cite

APA:

Rahman, P., Mcinnes, I., Deodhar, A., Schett, G., Mease, P.J., Shawi, M.,... Mcgonagle, D. (2022). GUSELKUMAB MAINTAINS RESOLUTION OF DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS THROUGH 2 YEARS FROM A PHASE 3 STUDY. In ANNALS OF THE RHEUMATIC DISEASES (pp. 826-827). LONDON: BMJ PUBLISHING GROUP.

MLA:

Rahman, P., et al. "GUSELKUMAB MAINTAINS RESOLUTION OF DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS THROUGH 2 YEARS FROM A PHASE 3 STUDY." Proceedings of the ANNALS OF THE RHEUMATIC DISEASES LONDON: BMJ PUBLISHING GROUP, 2022. 826-827.

BibTeX: Download